EYEG Eyegate Pharmaceuticals, Inc.

+0.05  (4%)
Previous Close 1.30
Open 1.32
Price To book 0.00
Market Cap 14.69M
Shares 10,878,000
Volume 181,102
Short Ratio 3.32
Av. Daily Volume 182,138

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 top-line data released July 2016. Further data released December 5, 2016. Phase 2b trial to be initiated 1H 2017.
Ocular inflammation and pain post cataract surgery
Phase 3 enrollment to be completed 3Q 2017. Top-line data due 4Q 2017
Non-infectious anterior uveitis

Latest News

  1. EyeGate Announces Completion of $10.0 Million Public Offering
  2. EyeGate Announces $10.0 Million Public Offering
  3. EYEG: Pipeline Progress Continues, Includes First Valeant Ocular Surgery Development Milestone
  4. Eyegate Pharma stock surges 11% after receiving Valeant milestone payment
  5. EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients
  6. EyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
  7. Today's Research Reports on Stocks to Watch: CombiMatrix and Eyegate Pharmaceuticals
  8. EyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel
  9. EYEG: Several Major Development Milestones Expected in 2017
  10. Top Biopharma Movers of the Past Week
  11. Biotech's Rally Shows No Signs of Slowing Down: Today's Reports on Eyegate Pharmaceuticals and VIVUS
  12. EyeGate Pharmaceuticals Licensing Deal Review and Breakdown
  13. ​Tiny Waltham biotech's market cap doubles after $103M Valeant licensing deal
  14. Valeant Acquires Eyegate Licensing Rights
  15. Tuesday’s Top Biopharma Movers
  16. Dow Higher for Eighth Straight Session as Retailers Rise
  17. Stock Futures Rise After Walmart, Home Depot Top Earnings Estimates